February 2026 Options Now Available For Teva Pharmaceutical Industries (TEVA)

TEVA is trading at $31.15; the $29 put (bid $0.50) would obligate purchase at $29 and net a $28.50 cost basis, is ~7% OTM and analytics put the odds of expiring worthless at 67%, implying a 1.72% return (14.30% annualized). The $31.50 call (bid $0.02) sold as a covered call would cap sale at $31.50, represents ~1% upside, carries a 48% chance to expire worthless and would yield 1.19% if called (or a 0.06% premium boost / 0.53% annualized if not). Implied volatilities are 65% for the put and 47% for the call versus a trailing 12-month volatility of 45%, and the piece frames these as option-income ideas while noting the tradeoffs of upside forgone and probabilities of expiration.

Analysis

Market structure: The option chain shows a pronounced put-call skew (put IV 65% vs call IV 47% vs realized 45%), signaling asymmetric demand for downside protection on TEVA (current stock $31.15). This benefits option sellers collecting YieldBoosts and brokers (flow), while hurting holders who pay elevated put premiums; it implies the market is pricing a >7% left-tail risk to Feb‑2026 even though short-term realized vol is lower.

Risk assessment: Tail risks include adverse regulatory rulings, generic litigation or surprise trial results that could drop TEVA >20% (material given $31 stock). Immediate risk (days) is IV/flow shifts around news; short-term (weeks–months) is earnings/product/court catalysts; long-term (quarters) is structural generics pricing and balance sheet stress. Hidden dependency: skew may reflect concentrated hedges by institutions — a rapid unwind would compress put IV and make short-put strategies less attractive.

Trade implications: Construct cash-secured short put exposure rather than naked: sell Feb‑2026 TEVA $29 put for $0.50 sized to 1–3% portfolio notional (effective buy at $28.50), or sell a $29/$26 put credit spread to cap downside and collect ~$0.50–$0.80 depending on fills. Alternatively, buy TEVA and sell Feb‑2026 $31.50 covered calls for $0.02 as a temporary yield boost only if willing to forgo >1% upside; avoid naked short calls.

Contrarian angles: The market may be overpricing left-tail risk—put IV > realized by ~20ppt—so selling defined-risk put spreads is likely underpriced edge if you are comfortable owning shares at $28.50 and can withstand a 20% drawdown. Conversely, if you expect positive pipeline/regulatory outcomes within 6–12 months, consider buy-call spreads (e.g., Feb‑2026 $32/$38) as low-cost asymmetric upside exposure.

Key Decisions for Investors

• Establish a cash-secured short position: sell-to-open Feb‑2026 TEVA $29 puts at ~$0.50 sized to 1–3% of portfolio notional (max effective purchase $28.50); set mental stop/hedge if TEVA trades below $24 (≈23% drop).
• If downside protection desired, sell Feb‑2026 $29/$26 put credit spreads (receive ~0.50–0.80) to limit max loss to ~$2.50 per share; allocate max 1–2% portfolio and close or roll if IV compresses >20 percentage points.
• For conservative income, buy TEVA at market and sell Feb‑2026 $31.50 covered calls for $0.02 only as short-term (<=3 months) yield enhancement; be prepared to be called away or roll to higher strikes if bullish.
• Opportunistic asymmetric long: buy Feb‑2026 $32/$38 call spreads if expect positive regulatory/catalyst within 6–12 months; risk per spread limited and benefits from potential IV convergence (pay <$1.00).
• Monitor: if put IV falls toward realized vol (<=50%) or institutional open interest drops by >30% within 2–4 weeks, tighten short-put positions or take profits—this signals unwinding of downside hedges and rapid premium decay.